Room: ePoster Forums
Purpose: To analyze and compare the outcomes of esophageal carcinoma treated with simultaneous integrated boost intensity-modulated radiation therapy and intensity-modulated radiation therapy (SIB-IMRT) and standarddose with intensity-modulated radiation therapy (SD-IMRT).
Methods: From January 2009 to August 2015, 232 patients of esophageal squamous cell carcinoma were treated with SIB-IMRT or SD-IMRT in the fifth department of radiation oncology of our hospital. Propensity score matching analysis was used to balance the variables differences of the two groups. The survival, patterns of failure and toxicities were observed and compared between the groups.
Results: here were 128 cases of patients included in the study after propensity scores matching. The l-, 3- and 5- year local control rates were 70.4%, 55.8% and 50.9% in the whole group, respectively. The l-, 3- and 5- year survival rates were 68.8%, 49.2% and 43.4%, respectively. The 1-, 3- and 5-year local control rates of SIB-IMRT and SD-IMRT group were 75.7%, 58.1%, 55.7% and 65.0%, 53.4%, 45.7%, respectively (Ï‡2=1.491ï¼ŒP=0.222). The 1-, 3- and 5-year survival rates of SIB-IMRT and SD-IMRT group were 73.4%, 48.4%, 46.2% and 64.1%, 50.0%, 40.1%, respectively (Ï‡2=0.424ï¼ŒP=0.515). Toxicity analysis showed â‰¥ grade 2 acute toxicities were not significant differentï¼ˆPï¼ž0.05ï¼‰.There were 72 cases of patients failed in the whole group, the failure rates were 56.3%. The failure rates of SIB-IMRT and SD-IMRT group were 56.3%(36/64), 56.3 %(36/64), respectively.
Conclusion: Esophageal squamous cell carcinoma treated with SIB-IMRT and SD-IMRTâ€™s toxicities have not significant difference, the two technologies were all well tolerated. There is no significant difference in local control rates and survival rates between the two groups, however, SIB-IMRT have better trend than SD-IMRT. SIB-IMRT could be a better choice in the treatment of advanced esophageal carcinoma.
Not Applicable / None Entered.